Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment.
158
TL;DR: The underpinning structure-function relationships and how the Fc has been engineered to produce an increasing number of antibodies that are appearing in the clinic with augmented abilities to treat cancer are revealed.
read more
Abstract: The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage innate immune effectors through interactions mediated by their fragment crystallizable (Fc) domain. By delivering Fc-Fc gamma receptor (FcγR) and Fc-C1q interactions, mAb are able to link exquisite specificity to powerful cellular and complement-mediated effector functions. Fc interactions can also facilitate enhanced target clustering to evoke potent receptor signaling. These observations have driven decades-long research to delineate the properties within the Fc that elicit these various activities, identifying key amino acid residues and elucidating the important role of glycosylation. They have also fostered a growing interest in Fc-engineering whereby this knowledge is exploited to modulate Fc effector function to suit specific mechanisms of action and therapeutic purposes. In this review, we document the insight that has been generated through the study of the Fc domain; revealing the underpinning structure-function relationships and how the Fc has been engineered to produce an increasing number of antibodies that are appearing in the clinic with augmented abilities to treat cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Monika Kumari,Ruei-Min Lu,Mu-Chun Li,Jhih-Liang Huang,Fu-Fei Hsu,Shih-Han Ko,Feng-Yi Ke,Shih-Chieh Su,Kang-Hao Liang,Joyce Pei-Yi Yuan,H.L. Chiang,Cheng-Pu Sun,I-Jung Lee,Wen-Shan Li,Hsing Pang Hsieh,Mi-Hua Tao,Han-Chung Wu +16 more
TL;DR: In this paper , the authors provide a framework for understanding the ongoing development efforts for different types of vaccines and therapeutics, including small molecule and antibody drugs, and summarize the clinical trials supporting the development and distribution of vaccines, small molecule drugs and therapeutic antibodies with broad spectrum activity against SARS-CoV-2 strains.
Payload diversification: a key step in the development of antibody–drug conjugates
TL;DR: A comprehensive overview of validated, forgotten and newly developed payloads with different mechanisms of action is presented in this article , where payload diversification is expected to play a key role as illustrated by a growing number of preclinical and clinical stage unconventional payload-conjugated ADCs.
Advances in antibody-based therapy in oncology
Sacha Zinn,Rodrigo Vazquez-Lombardi,Carsten Zimmermann,Puja Sapra,Lutz Jermutus,Daniel Christ +5 more
TL;DR: This review outlines key advances in the field with a particular focus on recent and emerging classes of engineered antibody therapeutic candidates, discusses molecular structure and mechanisms of action and provides updates on clinical development and practice.
99
Role of Fcγ receptors in HER2-targeted breast cancer therapy
Antonino Musolino,William J. Gradishar,Hope S. Rugo,Jeffrey L. Nordstrom,Edwin P. Rock,Fernanda I. Arnaldez,Mark D. Pegram +6 more
TL;DR: A worthwhile future goal in the treatment of Her2+ breast cancer is to promote combinatorial approaches that better eradicate HER2+ cancer cells via enhanced immunological mechanisms.
82
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
Xinghua Pang,Zhao-liang Huang,Tingting Zhong,Peng Zhang,Zhongmin Maxwell Wang,Michelle Xia,Baiyong Li +6 more
TL;DR: Cadonilimab (AK104) as discussed by the authors is a symmetric tetravalent bispecific antibody with a crystallizable fragment (Fc)-null design.
72
References
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more
TL;DR: The derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies is described here, made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor.
20.3K
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Julien Mazieres,Barbara Hermes,Filiz Çay Şenler,Tibor Csőszi,Andrea Fülöp,Jerónimo Rodríguez-Cid,Jonathan Wilson,Shunichi Sugawara,Terufumi Kato,Ki Hyeong Lee,Ying Cheng,Silvia Novello,Balazs Halmos,Xiaodong Li,Gregory M. Lubiniecki,Bilal Piperdi,Dariusz M. Kowalski,Keynote Investigators +22 more
TL;DR: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus pac litaxel or nab‐paclitaxel resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
3.2K
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
TL;DR: It is demonstrated that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB.
3K
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn,Aaron S. Mansfield,Aleksandra Szczesna,Libor Havel,Maciej Krzakowski,Maximilian Hochmair,Florian Huemer,György Losonczy,Melissa Lynne Johnson,Makoto Nishio,Martin Reck,Tony Mok,S. Lam,David S. Shames,Juan Liu,Beiying Ding,Ariel Lopez-Chavez,F. Kabbinavar,W. Lin,Alan Sandler,Stephen V. Liu +20 more
TL;DR: The addition of atezolizumab to chemotherapy in the first‐line treatment of extensive‐stage small‐cell lung cancer resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
2.8K
Fcγ receptors as regulators of immune responses
TL;DR: Recent studies addressing the multifaceted roles of FcRs for IgG (FcγRs) in the immune system are discussed and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases are discussed.